A co-development deal has been signed in 2019 with Bionexa Srl for the characterization of novel senolytic drugs from VSR’s Flav-x platform. The project, called FlavoLife, aims to develop innovative drugs to treat diseases associated with aging.

A co-development deal has been signed in 2019 with Bionexa Srl for the characterization of novel senolytic drugs from VSR’s Flav-x platform. The project, called FlavoLife, aims to develop innovative drugs to treat diseases associated with aging.

Siglato accordo commerciale con Bionexa Srl per ottenere nuovi senolitici dalla piattaforma farmaceutica Flav-x. Il progetto, chiamato FlavoLife, svilupperà farmaci innovativi per la cura di patologie dell’invecchiamento.